UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA ...

Going into 2025, we expect pharma brands and their advertising partners to use past learnings – and, more importantly – ...

Changing a cultural undertow is one of the hardest leadership challenges in any industry, and perhaps even more so in the ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The NHS is reported to be in line for a £30 billion ($40.7 billion) increase to its budget in the UK government's upcoming ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a ...

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan in advanced non-small cell lung cancer, ABBV-706 in high-grade neuroendocrine ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...